March 28, 2016
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Omeros reports $75.1 million net loss in 2015
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Omeros reported a net loss of $75.1 million, or $2.00 per share, in 2015 compared with $73.7 million, or $2.22 per share, in 2014, according to a company press release.
Total costs and expenses were reported at $84.7 million in 2015 compared with $70.5 million in 2014. The additional expenses were primarily attributed to the U.S. commercial launch of Omidria (1% phenylephrine/0.3% ketorolac injection).
The company reported $13.5 million in revenue in 2015, with $6.7 million in revenue from Omidria sales reported in the fourth quarter. Units of Omidria sold by the company’s wholesalers to ambulatory surgery centers and hospitals increased 74% in the U.S. in the fourth quarter compared with the third quarter.